Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma


Lilly

3Q Revenues: $5.2 billion (+14%)

3Q Loss: $465.6 million (earnings were $926.3 million in 3Q07)

YTD Revenues: $15.2 billion (+13%)

YTD Earnings: $1.6 billion (-26%)

Comments: Zyprexa sales were $1.2 billion in the quarter (+2%). Cymbalta sales were $716.4 million (+40%). Gemzar sales were $440.2 million (+12%). Humalog sales were up 19% to $432.6 million. Cialis sales were $376.6 million (+21%). Alimta sales were $313.9 million (46%). Strattera sales were $149.5 million (+15%). Byetta sales were $201.2 million (+22%). R&D expenses were $953.0 million in the quarter (+13%). The 3Q08 loss was due to charges totaling $1.5 billion related to pending and resolved Zyprexa investigations. In the quarter, the company completed the $64.0 million acquisition of SGX Pharmaceuticals, a San Diego-based biotechnology company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters